Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
AZD-0120 by Gracell Biotechnologies for Refractory Multiple Myeloma: Likelihood of Approval
AZD-0120 is under clinical development by Gracell Biotechnologies and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData,...
AZD-0120 by Gracell Biotechnologies for Relapsed Multiple Myeloma: Likelihood of Approval
AZD-0120 is under clinical development by Gracell Biotechnologies and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of AstraZeneca's AZD-0120?
AZD-0120 is a gene-modified cell therapy commercialized by AstraZeneca, with a leading Phase II program in Relapsed Multiple Myeloma;Refractory Multiple...